Section 4: Clinical Pharmacy Services

4CPS-178

DURABILITY OF TREATMENT AND REASONS FOR DISCONTINUATION OF DIMETHYL FUMARATE AND TERIFLUNOMIDE IN PATIENTS WITH MULTIPLE SCLEROSIS

4CPS-034

ANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-19

4CPS-033

EVALUATION OF THE EFFECTIVENESS OF REINDUCTION OR INTENSIFICATION WITH USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE

4CPS-177

OPTIMIZATION OF THE THERAPEUTIC MANAGEMENT OF PATIENTS ON ECMO IN THE PEDIATRIC INTENSIVE CARE UNIT

4CPS-032

THE USE OF LEAN METHODOLOGY IN CLINICAL PHARMACOKINETICS - A RETROSPECTIVE ANALYSIS

4CPS-031

THERAPEUTIC DRUG MONITORING OF CEFTAZIDIME/AVIBACTAM ADMINISTERED BY CONTINUOUS INFUSION: PK/PD TARGET ACHIEVEMENT AND CLINICAL OUTCOMES

4CPS-176

EVALUATION OF NIRMATRELVIR/RITONAVIR USE AND EFFECTIVENESS

4CPS-030

IMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES

4CPS-029

ECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES

4CPS-175

SEPSIS CODE: IMPROVING OUTCOMES FOR PATIENTS WITH SEPSIS

4CPS-028

DRUG BURDEN INDEX EVALUATION IN INSTITUTIONALIZED GERIATRIC PATIENTS AS A DEPRESCRIPTION STRATEGY

4CPS-027

COST SAVINGS IMPACT AND EFFECTIVENESS OF OMALIZUMAB OPTIMISATION IN REFRACTORY CHRONIC URTICARIA.

4CPS-026

EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN REDUCING POTASSIUM CONCENTRATIONS IN HOSPITALISED PATIENTS

4CPS-174

EFFECTIVITY AND SAFETY OF CYCLIN-DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER PATIENTS

4CPS-025

FREMANEZUMAB UTILISATION STUDY AND EFFECTIVENESS IN THE ‘REAL WORLD’

Pages